2 Biotech Pullback Targets Real Money Pro($)

Acadia and Neurocrine both have catalysts for growth; buy any weakness.
But it is not without some pain.
These stocks should be part of a strong first-quarter earnings season.
The stock keeps moving upwards, despite worries over pricing in biotech.
Their overseas business has been carrying them.
Both the headlines and the technical patterns are supportive of downside, but the dip buyers held things steady, and are inching back in.
The refusal to gap down at the open was probably a short-term negative.
Currency manipulation, dumping and intellectual property are crucial themes for the meeting.
The stock could have a meaningful bounce in this downtrend, but it is unlikely to reverse things overnight.
It will probably take a close above $38 to turn the chart more bullish.


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.